Search

Displaying results 291 - 300 of 4539 in total
  1. Drug

    Berotralstat

    go.drugbank.com/drugs/DB15982
    ApprovedInvestigational

    [A225106] Berotralstat was first approved by the FDA on December 3, 2020, as the first once-daily oral therapy to prevent angioedema attacks of HAE in adults and pediatric patients 12 years and older. … [A225166] Berotralstat is strictly used to prevent, but not treat, these attacks.[L26656] Developed by BioCryst Pharmaceuticals, berotralstat is marketed under the name Orladeyo as oral capsules.

  2. Drug

    Nuvaxovid

    go.drugbank.com/drugs/DB15810
    ApprovedInvestigational

    SARS-CoV-2, the causative agent of COVID-19, relies on the interaction between its trimeric spike (S) glycoprotein and angiotensin-converting enzyme 2 (hACE2) expressed on host cells in order to establish … [L49111] In the fall of 2024, an updated formulation covering the Omicron JN.1 subvariant was approved for use in Canada and the US.[L51394,L51399]

  3. Drug

    Dioxybenzone

    go.drugbank.com/drugs/DB11221
    ApprovedWithdrawn

    It absorbed UV-B and UV-AII rays. Dioxybenzone is an approved sunscreen ingredient in concentrations up to 3% [L2525].

  4. Drug

    Tradipitant

    go.drugbank.com/drugs/DB12580
    ApprovedInvestigational

    [A275353] Approved by the FDA on December 30, 2025, tradipitant is indicated for the prevention of vomiting induced by motion. … Tradipitant is a selective, high-affinity antagonist at human substance P/neurokinin-1 (NK-1) receptors.

  5. Drug

    Urethane

    go.drugbank.com/drugs/DB04827
    ApprovedWithdrawn

    Urethane, formerly marketed as an inactive ingredient in Profenil injection, was determined to be carcinogenic and was removed from the Canadian, US, and UK markets in 1963.

  6. Drug

    Peramivir

    go.drugbank.com/drugs/DB06614
    ApprovedInvestigational

    The development of peramivir has been supported by the US Department of Health and Human Services as part of the government's effort to prepare for a flu pandemic. … The injectable intravenous formulation of peramivir was approved by the FDA in September 2017 for the treatment of acute uncomplicated influenza to pediatric patients 2 years and older who have been symptomatic

  7. Drug

    Viloxazine

    go.drugbank.com/drugs/DB09185
    ApprovedInvestigationalWithdrawn

    It was first approved in the UK in 1974; however, the immediate-release formulation was discontinued due to business reasons unrelated to drug safety and efficacy. … In April 2021, an extended-release formulation of viloxazine under the brand name QELBREE was approved by the FDA for the treatment of attention deficit hyperactivity disorder (ADHD).[A247985]

  8. Drug

    Chloroprocaine

    go.drugbank.com/drugs/DB01161
    ApprovedInvestigational

    Both can be given as intrathecal injections for peripheral and central nerve block, but only the preservative-free formulation can be used for lumbar and caudal epidural blocks. … [A252952,L43382] Topical chloroprocaine for ophthalmic use was approved by the FDA in September 2022 for ocular surface anesthesia.[L43387]

  9. Drug

    Erythromycin

    go.drugbank.com/drugs/DB00199
    ApprovedInvestigationalVet approved

    [L5245] Erythromycin is widely used for treating a variety of infections, including those caused by gram-positive and gram-negative bacteria. … Erythromycin is a bacteriostatic antibiotic drug produced by a strain of Saccharopolyspora erythraea (formerly Streptomyces erythraeus) and belongs to the macrolide group of antibiotics which consists

  10. Drug

    Tralokinumab

    go.drugbank.com/drugs/DB12169
    ApprovedInvestigational

    US in December 2021. … It neutralizes IL-13 activity by inhibiting its ability to bind with receptors, thus helping to alleviate AD symptoms.